![Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK | Nature Medicine Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01548-7/MediaObjects/41591_2021_1548_Fig1_HTML.png)
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK | Nature Medicine
![Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant | Science Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant | Science](https://www.science.org/cms/10.1126/science.abl9551/asset/9233abaa-9229-44e5-a642-4f52fef1b488/assets/images/large/science.abl9551-f1.jpg)
Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant | Science
![Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination - ScienceDirect Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0092867422000769-fx1.jpg)
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination - ScienceDirect
![COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study | Scientific Reports COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-14016-0/MediaObjects/41598_2022_14016_Fig1_HTML.png)
COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study | Scientific Reports
![ALS Association Pressures FDA to Approve Amylyx Drug as Agency Cuts Phase III Trial Requirement - Xtalks ALS Association Pressures FDA to Approve Amylyx Drug as Agency Cuts Phase III Trial Requirement - Xtalks](https://i0.wp.com/xtalks.com/wp-content/uploads/2021/09/ALS-scaled.jpg?resize=1098%2C600&ssl=1)